LIBERATE trial reports that Tibolone use increases the risk of recurrence in breast cancer patients with vasomotor symptoms. However, there are some uncertainties and weak points in the study. Emerged questions are if interpretation of the results could be extrapolated to all breast cancer patients or there are specific subgroups that could use Tibolone without increasing relapse rate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.maturitas.2010.02.012 | DOI Listing |
Publication Analysis
Top Keywords
breast cancer
8
cancer patients
8
learned 'liberate'
4
'liberate' trial?
4
trial? liberate
4
liberate trial
4
trial reports
4
reports tibolone
4
tibolone increases
4
increases risk
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!